ClinicalTrials.gg
CompletedNCT05162274Updated Dec 11, 2024

Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

A Phase 1 interventional study of Lazertinib(G001) and Lazertinib(G002) in Healthy Adult Volunteers, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 20
38 · median 67
Started
2021
with 2 others
Phase 1
3 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
4 of 20
Yuhan Corporation

Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 1, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lazertinib

lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This Clinical Trial is an open, randomized, fasted, single-dose, oral administration 2-sequence, 2-period crossover study to assess bioequivalence of lazertinib between two formulations in healthy adult volunteers. The subjects administer 240mg of lazertinib of different formulations on the fasted status on each period and have a wash-out period for 14-21 days between the first and second period.

Read the detailed description

This clinical trial will be conducted in healthy male volunteers at Seoul National University Hospital (SNUH) Clinical Trial Center.

It is expected to take approximately 32 days from the first dosing of Investigational Product until the final follow-up visit. Subjects will be hospitalized twice for 4 nights and 5 days with 7-14 days of wash-out period, and one visit will be needed for safety evaluation between 14-17 days from the last dosing of the Investigational Product.

03

Conditions studied

  • Healthy Adult Volunteers

Keywords

  • YH25448
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, over 19 years of age
  • Male participants must agree to use an adequate method from the first to the third month after the last dose.
  • Participants must have a (BMI) between 18.5 and 30.0 kg/m2, inclusive(BMI = weight/height2), and body weight not less than 50 kg.
  • Subjects without congenital or chronic diseases within the last 3 years and without pathologic symptoms as determined by medical diagnosis.
  • Participants must be healthy on the basis of clinical laboratory tests performed at screening.
  • Informed of the nature of this study and voluntarily agree to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • medical or psychiatric illness.
  • Hypotension (SBP ≤ 90 mmHg or DBP ≤ 50 mmHg) or hypertension (SBP ≥ 150 mmHg or DBP ≥ 100 mmHg).
  • A marked baseline prolongation of .
  • Within 14 days prior to the first administration of product, use of prescription drugs or herbal medication, or within 7 days use of any over-the-counter medications
  • Participants who are planning COVID-19 vaccine within 14 days before the first intake of study drug and to the end of the trials.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants first received lazertinib(G001) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14\~21days, they then received lazertinib(G002) 240mg in a fasting state morning for 1 day.

    Drug: Lazertinib(G001) · Drug: Lazertinib(G002)

  • Experimental
    Group 2

    Participants first received lazertinib(G002) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14\~21days, they then received lazertinib(G001) 240mg in a fasting state morning for 1 day.

    Drug: Lazertinib(G001) · Drug: Lazertinib(G002)

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast of YH25448

    Area under the plasma concentration-time curve from zero to the time of the last quantitative concentration (AUC) of YH25448

    Time frame: 0 - 168 hours

  2. Cmax of YH25448

    Area under the plasma concentration-time curve from zero to the time of Maximum plasma concentration (Cmax) of YH25448

    Time frame: 0 - 168 hours

Secondary outcomes

  1. AUC0-72h of YH25448

    Area under the plasma concentration-time curve from zero to the time of the last quantitative concentration (AUC) of YH25448

    Time frame: 0 - 72 hours

  2. AUCinf of YH25448

    Area under the plasma concentration time curve from zero to infinity (AUC) of YH25448

    Time frame: 0 - 168 hours

  3. Tmax of YH25448

    Time to reach Cmax of YH25448

    Time frame: 0 - 168 hours

  4. t1/2 of YH25448

    Terminal half life (t1/2) of YH25448

    Time frame: 0 - 168 hours

  5. λz of YH25448

    Terminal rate constant of YH25448

    Time frame: 0 - 168 hours

  6. CL/F of YH25448

    The apparent plasma clearance (CL/F) of YH25448

    Time frame: 0 - 168 hours

  7. Vd/F of YH25448

    Apparent Volume of distribution of YH25448

    Time frame: 0 - 168 hours

07

Study locations

1 site
  • Seoul National University Hospital Clinical Trial Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jan 2022, 1 month.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 1 month is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 17, 2021
StartActual
Nov 30, 2021
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 14, 2022
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05162274
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Nov 30, 2021
Primary completion
Jan 14, 2022
Completion
Jan 14, 2022
Last update
Dec 11, 2024

Study contacts

Clinical Development and Medical Department
study director · Yuhan Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lazertinib

Start the discussion